Houston, TX, United States of America

John S Stehlin


Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 58(Granted Patents)


Company Filing History:


Years Active: 1996-2003

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by John S. Stehlin

Introduction

John S. Stehlin is a prominent inventor based in Houston, TX (US), known for his significant contributions to cancer treatment. With a total of 6 patents, he has focused on developing methods that utilize water-insoluble S-Camptothecin compounds for treating specific forms of cancer. His innovative approaches aim to improve the efficacy of cancer therapies.

Latest Patents

Among his latest patents, one notable invention is a method for treating cancer with water-insoluble S-Camptothecin of the closed lactone ring form and derivatives thereof. This method involves administering the compounds intramuscularly, orally, and transdermally. The focus on the closed-lactone ring intact enhances the therapeutic potential of the compounds, providing new avenues for cancer treatment.

Career Highlights

John S. Stehlin has dedicated his career to advancing cancer research and treatment methodologies. His work at the Stehlin Foundation for Cancer Research has been instrumental in developing innovative cancer therapies. His commitment to improving patient outcomes through research and innovation is evident in his patent portfolio.

Collaborations

Throughout his career, John has collaborated with notable professionals in the field, including Beppino C. Giovanella and Anthony J. Kozielski. These collaborations have further enriched his research and contributed to the development of effective cancer treatment methods.

Conclusion

John S. Stehlin's contributions to cancer treatment through his innovative patents and research collaborations highlight his dedication to improving healthcare outcomes. His work continues to inspire advancements in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…